Diagnostic Value of Heart-type Fatty Acid Binding Protein in Group of Patients with NSTEMI at the Time of Application for Medical Care


Yevhen Sid
Oleksandr Kulbachuk


The relevance of the early detection of myocardial necrosis is due to the difficulties of differential diagnosis in the first hours of the development of acute coronary syndrome. Therefore, the doctors of the first contact, as before, are interested in an early cardiac marker and the presence of tests based on it. Heart fatty acid binding protein (h-FABP) is a cardiac marker that increases in the blood to diagnostic values after just one hour from the beginning of clinical manifestations.

The objective: to determine the diagnostic value of heart fatty acid binding protein in group of patients with NSTEMI.

Materials and methods. We examined 280 patients with STEMI, 91 patients with NSTEMI, 76 with stable angina pectoris. Blood samples were taken from all patients at the first contact to determine troponin I, a heart fatty acid binding protein and CPK-MB. Patients with NSTEMI were divided into three subgroups: the first – up to 3 hours from the onset of symptoms, the second – from 3 to 6, the third from 6 to 12. The level of heart fatty acid binding protein in plasma was determined by enzyme immunoassay.

Results. The early detection of AMI in people visiting primary care doctors with chest pain continues to be a challenge. Undoubtedly, cardiac troponins are the “gold standard” for the diagnosis of AMI, but early detection of these can give a negative result. The results of the studies show a high diagnostic efficacy of h-FABP in the early diagnosis of AMI, and it is superior in sensitivity (in the first hours from the onset of the disease) to cardiac troponins. So, for example, in the subgroup of patients with the onset of symptom manifestation up to 3 hours for h-FABP with a cut-off >0,48 ng/ml, the sensitivity was 92.7 % and specificity was 97,3 % (AUC=0,99; 95 % CI AUC 0,942–0,998). In the same subgroup, troponin I had a specificity of  22,0 %, with cut off >0,84 ng/ml (AUC=0,71; 95 % CI AUC 0,615–0,787).

Conclusions. The level of cardiac protein that binds fatty acids is significantly increased in patients with acute myocardial infarction compared with stable coronary heart disease.


How to Cite
Sid, Y., & Kulbachuk, O. . (2021). Diagnostic Value of Heart-type Fatty Acid Binding Protein in Group of Patients with NSTEMI at the Time of Application for Medical Care. Family Medicine, (5-6), 70–74. https://doi.org/10.30841/2307-5112.5-6.2020.225454
Author Biographies

Yevhen Sid, Zaporizhzhya Medical Academy of Postgraduate Education

Yevhen V. Sid,

Department of Emergency Medicine

Oleksandr Kulbachuk, Zaporizhzhya Medical Academy of Postgraduate Education

Oleksandr S. Kulbachuk,

Department of General Practice–Family Medicine with Dermatovenereology and Psychiatry Courses


Agnello, L., Bivona, G., Novo, G., Scazzone, C., Muratore, R., Levantino, P., ... & Ciaccio, M. (2017). Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study. Scandinavian journal of clinical and laboratory investigation, vol. 77, no. 6, pp. 428–432.

Anvari, M. S., Karimi, M., Shafiee, A., Boroumand, M., Bozorgi, A., Sedaghat, R., & Jalali, A. (2018). Complementary diagnostic value of heart type fatty acid-binding protein in early detection of acute myocardial infarction. Critical pathways in cardiology, vol. 17, no. 1, pp. 43–46.

Glatz, J. F., & Renneberg, R. (2014). Added value of H-FABP as a plasma biomarker for the early evaluation of suspected acute coronary syndrome. Clinical Lipidology, vol. 9, no. 2, pp. 205–220. doi: 10.2217/clp.13.87

Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., ... & Hindricks, G. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal, vol. 39, no. 2, pp. 119–177. doi.org/10.1093/eurheartj/ehx393

Kabekkodu, S. P., Mananje, S. R., & Saya, R. P. (2016). A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. Journal of clinical and diagnostic research: JCDR, vol. 10, no. 1, pp. OC07–OC10.

Kingma, J. G. (2018). Myocardial Infarction: An Overview of STEMI and NSTEMI Physiopathology and Treatment. World Journal of Cardiovascular Diseases, vol. 8, no. 11, pp. 498–517. doi: 10.4236/wjcd.2018.811049

Nielsen, S. H., Mouton, A. J., DeLeon-Pennell, K. Y., Genovese, F., Karsdal, M., & Lindsey, M. L. (2019). Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes. Matrix Biology, no. 75, pp. 43–57.

Otaki, Y., Watanabe, T., & Kubota, I. (2017). Heart-type fatty acid-binding protein in cardiovascular disease: A systemic review.Clinica Chimica Acta, no. 474, pp. 44–53.

Рудень, В. В., & Ковальська, І. М. (2019). Аналіз і прогноз показників смертності з причини гострого інфаркту міокарда серед населення в Україні. Україна. Здоров’я нації, no. 1, pp. 131–139.

Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., ... & Bucciarelli-Ducci, C. (2019). Fourth universal definition of myocardial infarction (2018). European heart journal, vol. 40, no. 3, pp. 237–269. doi. org/10.1093/eurheartj/ehy462

Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., ... & White, H. D. (2012). Third universal definition of myocardial infarction. European heart journal, vol. 33, no. 20, pp. 2551–2567. doi.org/10.1093/med/9780199687039.003.0041

Vupputuri, A., Sekhar, S., Krishnan, S., Venugopal, K., & Natarajan, K. U. (2015). Heart-type fatty acid-binding protein (HFABP) as an early diagnostic biomarker in patients with acute chest pain. Indian heart journal, vol. 67, no. 6, pp. 538–542. doi: 10.1016/j.ihj.2015.06.035